Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.56
+0.35 (2.87%)
At close: Aug 11, 2025, 4:00 PM
12.57
+0.01 (0.08%)
After-hours: Aug 11, 2025, 7:32 PM EDT
Ocular Therapeutix Employees
Ocular Therapeutix had 274 employees as of December 31, 2024. The number of employees increased by 7 or 2.62% compared to the previous year.
Employees
274
Change (1Y)
7
Growth (1Y)
2.62%
Revenue / Employee
$206,803
Profits / Employee
-$791,051
Market Cap
2.19B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 274 | 7 | 2.62% |
Dec 31, 2023 | 267 | -7 | -2.55% |
Dec 31, 2022 | 274 | 46 | 20.18% |
Dec 31, 2021 | 228 | 47 | 25.97% |
Dec 31, 2020 | 181 | 20 | 12.42% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OCUL News
- 6 days ago - Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 6 weeks ago - Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewsWire
- 3 months ago - Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Ocular Therapeutix™ to Participate in Two Investor Conferences in April - GlobeNewsWire
- 5 months ago - Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - Benzinga